Welcome to our dedicated page for 60 DEGREES PHARMACEUTICALS SEC filings (Ticker: SXTPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on 60 DEGREES PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into 60 DEGREES PHARMACEUTICALS's regulatory disclosures and financial reporting.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.
The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.
60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.
The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.
60 Degrees Pharmaceuticals, Inc. (SXTP) reports that Nasdaq staff has determined to delist its common stock and warrants from The Nasdaq Capital Market. Nasdaq concluded the company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2), and that it is not eligible for the usual 180‑day grace period because it completed a 1‑for‑5 reverse stock split on February 24, 2025 under Listing Rule 5810(c)(3)(A)(iv). The company’s warrants are also subject to delisting under Listing Rule 5560(a) because the underlying common stock is subject to delisting. The company has paid a $20,000 hearing fee and requested an appeal to a Nasdaq hearings panel, which temporarily stays any trading suspension and the filing of a Form 25‑NSE until the panel issues its decision.
60 Degrees Pharmaceuticals, Inc. approved a reverse stock split of its common stock at a final ratio of one-for-four. The company’s stockholders approved the amendment to its Certificate of Incorporation on October 8, 2025, after a recommendation from the board of directors. The company then filed a Certificate of Amendment in Delaware on January 14, 2026, which becomes effective at 12:01 a.m. Eastern Time on January 20, 2026.
At the effective time, every four shares of issued and outstanding common stock are automatically combined and converted into one share. The company is not issuing fractional shares; any fractional amounts are rounded up to one whole share. The company also issued a press release about the reverse split on January 15, 2026, which is included as an exhibit.
60 Degrees Pharmaceuticals, Inc. filed a current report to share that its Chief Executive Officer, Geoffrey Dow, is scheduled to provide investor information beginning on September 9, 2025. The company prepared an investor presentation for this event, which is included as Exhibit 99.1 to the report.
The materials in the presentation are stated to be current as of September 9, 2025, and the company notes it does not undertake to update this information in the future. The presentation is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed for liability purposes under certain securities laws.
60 Degrees Pharmaceuticals prospectus supplement (Form 424B5) outlines the securities being offered and includes extensive discussion of Tafenoquine (Arakoda) clinical and market opportunities across human and veterinary tick-borne and antifungal indications. The document highlights company-commissioned market research (300 prescribers, 6,000 consumers, claims data) and presents incidence and prevalence estimates: up to 38,000 potentially treatable acute babesiosis cases annually, an estimated minimum ~7,900 persistent babesiosis insurance-claim cases per year, and a modeled tafenoquine-treated market as high as 380,000 annual chronic persistent cases (≈$245 million annual sales; cumulative 1.71 million patients and $1.1 billion sales through patent expiry in 2035). It cites prior cooperative R&D with the U.S. Army and references patents, outstanding warrants (7,587,594 shares at $5.82 average exercise), options (28,437 shares at $23.64 average exercise) and reserved shares (57,068) under the 2022 Plan. The supplement also describes debt securities, unit and trustee provisions, global security/book-entry mechanics and disclosure obligations incorporated by reference to SEC filings.
60 Degrees Pharmaceuticals, Inc. reported an item on an 8-K disclosing a Sales Agreement dated September 5, 2025 between the company and H.C. Wainwright & Co., LLC related to its securities. The filing lists the Sales Agreement as Exhibit 1.1 and includes a legal opinion and consent from Sichenzia Ross Ference Carmel LLP as Exhibits 5.1 and 23.1. The document is signed by Geoffrey Dow, Chief Executive Officer and President.
The filing supplies exhibit-level detail but does not disclose the economic terms, offering size, pricing mechanics, or expected timing for any sales under the agreement. No financial tables, revenue, or earnings data are provided.
60 Degrees Pharmaceuticals, Inc. is soliciting proxies for its upcoming annual meeting to elect five directors and seek shareholder approval on several proposals. The Board recommends voting FOR the election of the five nominees, an amendment to the 2022 Equity Plan to add 250,000 shares, an amendment to the Certificate of Incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10 (to be chosen by the Board), the ratification of RBSM LLP as independent auditor for fiscal 2025, and a proposal to adjourn if additional votes are needed.
The reverse split, if approved, will combine outstanding shares automatically, eliminate fractional shares (entitling holders to whole shares instead), proportionately adjust outstanding options and warrants, and leave authorized shares at 150,000,000. The Board has not recommended votes on other potential matters; proxies may vote discretionarily on such items.
Insider option grant and ownership change at 60 Degrees Pharmaceuticals — Kristen Landon, the company’s Chief Operating Officer, was granted 4,167 stock options with an exercise price of $6.85. The options vest in five equal annual tranches beginning December 31, 2024, and have a 10-year maximum term. After the grant, Landon beneficially owns 4,167 underlying shares directly. The filing notes it was submitted late due to an administrative error and that all figures were retroactively adjusted for a 1-for-5 reverse stock split effected by the issuer.
Kristen Landon, Chief Operating Officer and director of 60 Degrees Pharmaceuticals, Inc., reports acquiring 4,540 shares of the issuer's common stock on 01/17/2025. The reported acquisition was at no cash price ($0) and leaves Ms. Landon with 4,540 shares held directly. The filing notes it was submitted late due to an inadvertent administrative error and that the reported share totals were adjusted to reflect a 1-for-5 reverse stock split effective 02/24/2025. The Form 4 is signed by the reporting person on 08/14/2025. All information is limited to this single non-derivative purchase; no derivative transactions or prices other than $0 are reported.